🚀 VC round data is live in beta, check it out!
Cognition Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Cognition Therapeutics and similar public comparables like Zomedica, Cassava Sciences, Vistin Pharma, Darya-Varia Laboratoria and more.
Cognition Therapeutics Overview
About Cognition Therapeutics
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.
Founded
2007
HQ
Employees
28
Website
Sectors
Financials (LTM)
EV
$70M
Cognition Therapeutics Financials
Cognition Therapeutics reported last 12-month revenue of —.
In the same LTM period, Cognition Therapeutics generated — in gross profit and had net loss of ($25M).
Revenue (LTM)
Cognition Therapeutics P&L
In the most recent fiscal year, Cognition Therapeutics reported revenue of — and EBITDA of ($23M).
Cognition Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | — | XXX | ($23M) | XXX | XXX | XXX |
| Net Profit | ($25M) | XXX | ($23M) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Cognition Therapeutics Stock Performance
Cognition Therapeutics has current market cap of $106M, and enterprise value of $70M.
Market Cap Evolution
Cognition Therapeutics' stock price is $1.19.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $70M | $106M | 0.0% | XXX | XXX | XXX | $-0.26 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialCognition Therapeutics Valuation Multiples
Cognition Therapeutics trades at (3.0x) EV/EBITDA.
Cognition Therapeutics Financial Valuation Multiples
As of April 20, 2026, Cognition Therapeutics has market cap of $106M and EV of $70M.
Equity research analysts estimate Cognition Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Cognition Therapeutics has a P/E ratio of (4.2x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $106M | XXX | $106M | XXX | XXX | XXX |
| EV (current) | $70M | XXX | $70M | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (3.0x) | XXX | XXX | XXX |
| EV/EBIT | (1.8x) | XXX | (2.9x) | XXX | XXX | XXX |
| P/E | (4.2x) | XXX | (4.5x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (2.9x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Cognition Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Cognition Therapeutics Margins & Growth Rates
Cognition Therapeutics' revenue in the last fiscal year grew by —.
Cognition Therapeutics' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.9M for the same period.
Cognition Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | — | XXX | (31%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.9M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Cognition Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Cognition Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Zomedica | XXX | XXX | XXX | XXX | XXX | XXX |
| Cassava Sciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Vistin Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Darya-Varia Laboratoria | XXX | XXX | XXX | XXX | XXX | XXX |
| SynAct Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Cognition Therapeutics M&A Activity
Cognition Therapeutics acquired XXX companies to date.
Last acquisition by Cognition Therapeutics was on XXXXXXXX, XXXXX. Cognition Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Cognition Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialCognition Therapeutics Investment Activity
Cognition Therapeutics invested in XXX companies to date.
Cognition Therapeutics made its latest investment on XXXXXXXX, XXXXX. Cognition Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Cognition Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Cognition Therapeutics
| When was Cognition Therapeutics founded? | Cognition Therapeutics was founded in 2007. |
| Where is Cognition Therapeutics headquartered? | Cognition Therapeutics is headquartered in United States. |
| How many employees does Cognition Therapeutics have? | As of today, Cognition Therapeutics has over 28 employees. |
| Who is the CEO of Cognition Therapeutics? | Cognition Therapeutics' CEO is Lisa Ricciardi. |
| Is Cognition Therapeutics publicly listed? | Yes, Cognition Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Cognition Therapeutics? | Cognition Therapeutics trades under CGTX ticker. |
| When did Cognition Therapeutics go public? | Cognition Therapeutics went public in 2021. |
| Who are competitors of Cognition Therapeutics? | Cognition Therapeutics main competitors are Zomedica, Cassava Sciences, Vistin Pharma, Darya-Varia Laboratoria. |
| What is the current market cap of Cognition Therapeutics? | Cognition Therapeutics' current market cap is $106M. |
| Is Cognition Therapeutics profitable? | No, Cognition Therapeutics is not profitable. |
| What is the current net income of Cognition Therapeutics? | Cognition Therapeutics' last 12 months net income is ($25M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.